ZVRA - חוב כולל להון Zevra Corp

Zevra Therapeutics (ZVRA) has established a closed ecosystem for the therapy of rare pediatric brain pathologies by integrating genetic testing with patient support. The price visualization on GURU.Markets, which assists in the basic asset valuation, shows that the debt-to-equity ratio is 0.01. Zevra Therapeutics (ZVRA) is updating its analytics software while outsourcing drug production. However, the small market size and pressure from biotech behemoths create risks of low profitability.

Zevra Therapeutics (ZVRA) faces moderate cash flow volatility due to a limited patient base. Under these conditions, the total debt-to-equity ratio determines the company's ability to service its obligations using its own funds. This metric measures the proportion of borrowed resources within the balance sheet structure relative to shareholders' equity. An increase in this ratio signals overleverage, while a decrease indicates conservative management. The price action on this chart allows for the timely identification of financial stability risks.